|
|
|
|
|
Anibal Pedraza, Lucia Gonzalez, Oscar Deniz and Gloria Bueno
HER2 overexpression is a prognostic and predictive factor observed in about 15% to 20% of breast cancer cases. The assessment of its expression directly affects the selection of treatment and prognosis. The measurement of HER2 status is performed by an e...
ver más
|
|
|
|
|